Influencing factors of the recurrence after neoadjuvant therapy in HER2-positive breast cancer.

• DOI: 10.1200/jco.2022.40.16_suppl.e12608
• Publication Date: 2022-06-06T15:52:41Z
• Authors: Serafin Morales M...; Ariadna Gasol Cud"S; Noemí Tuset Der-a...; Alvaro Rodriguez; Ana Velasco Sanchez; Felip Vilardell; Douglas Sanchez G...; Carles Canosa Mor...; Jordi Melé Olivé
• Keywords: Neoadjuvant Therapy; Complete response

e12608 Background: HER2-positive breast cancer is the more suitable subtype to perform a neoadjuvant therapy with chemotherapy and antiHER2 because high pathologic response significance survival. However, despite this percentage of pathological responses, there are still recurrences that can affect Methods: We analyze cohort 287 HER-2 positive treated according current guidelines, find factors could induce recurrence. Results: Median age was 56 (28-89), median tumor size 37 mm (12-140), 145 (50%) had nodal involvement, estrogen receptor in 152 patients (53%) ki67 expression 41% (3-95). HER2 by inmunohistochemistry 2+ 83 (29%) 3+ 204 (71%). A total 50% complete (pCR) rate detected 54 (18,8%) relapsed. 17 pCR (12%) without (25%) recurrence (OR 4,31, p: 0,003). The most influenced relapse group were: initial (greater than 5 cm) 30% relapses, axillary involvement (19%) cases +3 negative (17%). In pCR, frequent +2 (40%), (43%), greater cm (38%) (38%). Conclusions: Although continues be important factor avoid relapse, other must considered as determinants achieving pCR. Initial poor prognostic reaching up so adjuvant interventions should after treatment.